J&J sales
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer & Specialty Pharmaceuticals "will maintain a limited number of products containing pseudoephedrine for behind the counter sale" but "is in the process of reformulating our products that contain this ingredient," J&J VP- Investor Relations Helen Short stated during a third-quarter earnings call Oct. 18. The "negative impact" of restrictions implemented on products containing pseudoephedrine was responsible for offsetting sales growth for the McNeil division during the third quarter, Short added. The McNeil franchise had operational growth of 11% for the third quarter, six points of which were a result of a reclassification of certain OTC products from the pharmaceutical division to McNeil in January, Short said. Imodium, Pepcid and Motilium were among those reclassified (1"The Tan Sheet" July 25, 2005, p. 10). Global consumer sales of $2.2 bil. for the quarter represented an increase of 10.2% over the prior-year period, the firm said...